The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
Ok, but don't forget this all started AFTER he did a video conference to all, bragging about how many people were on the call. The real problem is that everyone, and I mean everyone has seen through him. The guy has no credibility left.
Maybe the BOD have told him to keep his mouth shut.........if that is the case, that is admitting the guy is a liability.
Remember.........if you believed their tittle tattle and waffle, and sold your shares on the back of their advice, they are now holding them and looking at 15% return at least, just on the past 2 hours.
So lesson learnt by the weak I hope.........only read RNS's..........do not take at face value anything written by people you do not know or trust....especially when written with a clear intent to drop the SP.
Why would anyone talk down their own investment? .... answer they wouldn't........because they didn't own any...but they do now..YOURS
We are not responding to Khans' headers .........we are all using different ones............we all know how the gamer is played....the only ones using his headers are his brothers
Good luck Magoo............if we trust Lorna....which I believe we all do, I certainly do, we all making similar investments as yours with a strong belief we are all riding a winner here.
Gut feeling goes a long way for me, and mine was to buy a lot at 0.63 and just hold. Currently up 290% but I am not going anywhere...this will see me ok, my kids ok and my grandkids ok.
Next time certain visible doom mongers appear..........get some cash ready to buy in, never ever sell based on tittle tattle from keyboard warriors like Johnny and Jenny .
Let them take the price down and play them at their own game and buy more for your own benefits.
Just taken this from another BB and it also true here
Navigating the intersection of financial markets and the development of life-saving cancer therapies presents a profound ethical dilemma. At the heart of this issue is a choice between prioritizing financial gain or valuing human life. Personally I hold the conviction that the advancement of medical treatments- particularly those with the potential to save lives should be elevated above monetary interests. I would willingly donate my shares to see this having the best chance of success.
Conversely, I recognize that the perspective of profiting from the challenges faced by companies striving to develop cancer therapies can be seen as deeply controversial if not morally reprehensible. To actively undermine or bet against the success of these endeavour's for personal financial gain could be viewed as indirectly contributing to the loss of lives. In my view this borders on the unethical (at best) at worst- and I know this is controversial but I will caveat this with the general statement that forgives all "IMO" it is tantamount to manslaughter (ie causing the unintentional death of others - who could have otherwise received a beneficial treatment).
I believe that scientific advancements especially those with the power to cure diseases and save lives should be shielded from the volatility and the speculative nature of financial markets through short selling etc. I personally think there should be a moral imperative to support and protect the development of vital medical treatments from actions that could hinder their success. In short I would champion the pursuit of humanity over the pursuit of wealth.
Simple courtesy to all, not just us peasants, is required to stop the flack they are getting and worsening the reputation of the company and themselves.
That is assuming they care, because Burrows will have pocketed another £1500 in the short time it took me write this.
Sitian.......who do you believe..........a knight of the realm and his brilliant scientists who also do presentations to their peers and video conferences to the world............or Wayne and Waynetta telling you to sell from their one bedroomed flat in Croydon while they eat their pizzas and burgers for breakfast !!!!!!
These are intelligent people, in all areas of the Business. They would not have let the SP drop 60% and then decide to raise funds.......think about it guys.........this is a co-ordinated attack to get the weak to sell, and the germs will be picking them all up willingly and laughing at you as they do it.
2023 Earnings ; UK £0.073 LOSS PER SHARE
Vs 2022 UK £ 0.067 Loss per share
Net Loss uk£10.8m ( loss widened by 61% from last year)
Earnings have declined 30% per year average for the past 5 years
Have less that 1 years cash remaining ( but Burrows and family and friends still ge big increases)
Sold less than $1m in the US which is supposed to be the market we are concentrating on.
Make your own mind up if you are being ripped off.
From November 8th 2023 RNS.
Oxford BioDynamics strengthens commercial leadership with new SVP of Business and Corporate Development
· Appointment of industry veteran Dr Steven Arrivo as SVP business and corporate development.
· Dr Arrivo to focus on marketing, partnering and sales of the recently launched EpiSwitch Prostate Screening (PSE) test.
Oxford, UK - 8 November, 2023 - Oxford BioDynamics, Plc (AIM: OBD, the Company), a biotechnology company developing precision medicine tests based on the EpiSwitch® 3D genomics platform has appointed Dr Steven Arrivo as Senior Vice President of Business and Corporate Development. Dr Arrivo brings over 20 years of science and industry experience along with an established track record in business and corporate development within personalized medicine across big pharma, biotech and molecular diagnostics companies.
Dr Arrivo joins Oxford BioDynamics from CellCarta Biosciences (formerly Caprion) where he spent five years in Business Development, as Senior Director and Vice President. Prior to that he was at Biodesix and Ventana Medical Systems. Before then, he spent four years at Pfizer in various R&D roles and he began his career at Merck & Co., Inc. as a Senior Project Scientist following several academic research positions. Dr Arrivo holds a Bachelor's degree in Chemistry from the University of Eastern Illinois, and a Master's degree in Synthetic Organic and Inorganic Chemistry and Ph.D. in Physical Chemistry from Northwestern University. He completed Postdoctoral studies in Physical Chemistry at Columbia University.
At OBD, Dr Arrivo's role will be to implement effective marketing and sales strategies for the newly launched EpiSwitch® PSE prostate cancer detection test. His specific focus will be to grow sales in the US market, where he has considerable experience of launching products.
Dr Jon Burrows, the well known xxxxxxxxxxxxx and CEO of Oxford BioDynamics, commented:
"Having someone of Steve's calibre in the OBD commercial team is a real endorsement of our technology and its potential. He has a wealth of experience in this industry and the ideal skill set to drive our commercial efforts with PSE. His leadership and knowledge will be invaluable across all areas of our growing product portfolio."